Synergy Pharmaceuticals Inc. is a biopharmaceutical company headquartered in New York, New York, focused on the development and commercialization of gastrointestinal therapies. The company’s proprietary platform, based on analogs of the human peptide uroguanylin, includes its primary commercial product, TRULANCE, used to treat chronic idiopathic constipation and irritable bowel syndrome with constipation. Synergy holds approximately 33 issued U.S. patents and employs 280 people. The company is publicly traded on the NASDAQ under the symbol SGYP.